

*Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody<sup>®</sup> molecules and Albumod<sup>®</sup> half-life extension technology.*

In the research operations department, we develop and characterize new Affibody<sup>®</sup> molecules. The ones with the most interesting properties are then selected as CD (Candidate Drug). In the spring of 2026, we are planning a 30 credits degree project with the preliminary title:

## **Development of fluorescence labeled HSA assays for visualization of cell-binding Affibody<sup>®</sup> molecules**

### **Background**

Affibody AB runs several early discovery projects aimed at identifying novel, clinically relevant Affibody<sup>®</sup> molecules. Candidate molecules are subjected to a broad spectrum of *in vitro* pharmacology studies to characterize their activity. A key aspect to support Affibody's innovative radiopharmaceutical pipeline is to identify Affibody<sup>®</sup> molecules with strong and specific binding to cellular receptor targets.

### **Execution**

Cell binding assays are commonly used to identify molecules that can bind to tumor cell targets. If the targeting molecule is a monoclonal antibody there are several commercially available reagents for detection of bound antibodies. With Affibody<sup>®</sup> molecules an extra staining step with proprietary antibody reagents are currently needed. The project aims to develop an alternative way of visualizing cell-bound Affibody<sup>®</sup> molecules by utilizing the strong interaction between the albumin-binding domain (ABD), often fused to Affibody<sup>®</sup> molecules for half-life extension, and human serum albumin (HSA).

Key features included in the project:

- Evaluate different fluorophores and techniques for labeling HSA.
- Perform routine cell culture in sterile environment.
- Develop and optimize cell staining protocols for different tumor *in vitro* cell models.
- Analyze stained cells with flow cytometry and in plate reader.
- Quality testing of final new protocol.

Optional activities:

- Evaluate stained cells with fluorescence microscopy and image analysis.

### **Supervisor**

Lotta Tengroth, PhD. If you have any questions, please contact: [lotta.tengroth@affibody.se](mailto:lotta.tengroth@affibody.se). Affibody AB, Scheeles väg 2, 171 65 Solna.

### **Application**

If you are interested, send your personal letter and CV to [jobs@affibody.se](mailto:jobs@affibody.se) latest November 14<sup>th</sup>, 2025 and mark your application with **EX049**.